CURE Pharmaceutical Holding Corp. (CURR)
|Net Income (ttm)||-15.04M|
|Trading Day||January 15|
|Day's Range||1.26 - 1.43|
|52-Week Range||0.96 - 2.85|
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development compa...
CURE Pharmaceutical to Present at LD Micro on December 15, Schedules Investor Video Webcast for December 17
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTCQB: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness produc...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products...
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Closes $10 Million Financing
CURE Pharmaceutical's® Wholly Owned Subsidiary SeraLabs® Introduces Nutri-Strips™, a Revolutionary Oral Thin Film Strip Technology
LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding (OTCQB: CURR) wholly owned subsidiary Sera Labs is challenging the status quo of the health and wellness sector by br...
CURE Pharmaceutical Completes $20 Million Acquisition of Sera Labs, a Leading Health, Wellness and Beauty Brand Marketing and Multi-Channel Distribution Platform Company
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October.
- CURE will present at the LD 500 Virtual Conference, September 4 at 8:20 am PDT -
Sera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, to be acquired by CURE Pharmaceutical in a $20 Million Transaction
SHERMAN OAKS, Calif.--(BUSINESS WIRE)-- #Beauty--Sera Labs, a Leader in the CBD Industry to be acquired by CURE Pharmaceutical in a $20 Million Transaction
CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel
Significantly higher serum concentration and absorption Showcases CUREform™ encapsulation and oral thin film technology Significantly higher serum concentration and absorption Showcases CUREfo...
OXNARD, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical, (OTC: CURR), an innovative drug delivery and development company, today announced that its 25,000 square foot manufactu...
- Jonathan Berlent Appointed to Newly Created Role - - Jonathan Berlent Appointed to Newly Created Role -
CURE Pharmaceutical Announces Exercise of Warrants for Cash Proceeds of Approximately $1.4 Million and Completes Earn Out Related to 2019 Acquisition
OXNARD, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR), an innovative drug delivery company that is developing novel ways to deliver active ingredien...
CURE Pharmaceutical Holding, an integrated drug delivery and development company, focuses on improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. The company is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. It offers CURE 3068 (CUREfilm Sleep), a melatonin-containing sleep aid CUREfilm oral dissolving film (ODF) that is used as a dietary supplement under the brand name ID Life Sleep Strips; and CURE... [Read more...]
Drug Manufacturers-Specialty & Generic
|Stock Exchange |
|Ticker Symbol |
In 2019, CURR's revenue was $623,000, an increase of 6.68% compared to the previous year's $584,000. Losses were -$21.36 million, 105.4% more than in 2018.